New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:08 EDTARNAArena Pharmaceuticals reports that Eisai increases sales force for Belviq
Arena Pharmaceuticals reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for Belviq by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the U.S.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
18:56 EDTARNAOn The Fly: After Hours Movers
HIGHER: Regulus Therapeutics (RGLS), up 8.7% after the company announced that it will present new preclinical data on RG-012 for kidney disease... Palatin Technologies (PTN), up 9.6% after director Robert deVeer Jr. buys 10,000 shares of common stock... Arena Pharmaceuticals (ARNA), up 4.7% after CEO Jack Lief announced his retirement and Harry Hixson was named interim CEO... DuPont (DD), up 5.9% after CEO and chair Ellen Kullman retires... Ruckus Wireless (RKUS), up 4.9% after joining the S&P 600... Starz (STRZA), up 10.1% after the LA Times reports that Lionsgate (LGF) is in advanced talks to merge with Starz. DOWN AFTER EARNINGS: Container Store (TCS), down 10.4%. ALSO LOWER: Sarepta Therapeutics (SRPT), down 3.8% after filing to sell $125M of common stock... Haemonetics (HAE), down 12.2% after lowering its fiscal 2016 outlook... Energy XXI (EXXI), down 8.3% after filing a $500M mixed securities shelf... Mallinckrodt (MNK), down 1.6% after announcing that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6.
16:20 EDTARNAArena Pharmaceuticals CEO Jack Lief retires, Harry Hixson named interim CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use